• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

通过针对erbB-2的细胞内抗体进行靶向肿瘤杀伤。

Targeted tumor killing via an intracellular antibody against erbB-2.

作者信息

Deshane J, Siegal G P, Alvarez R D, Wang M H, Feng M, Cabrera G, Liu T, Kay M, Curiel D T

机构信息

Gene Therapy Program, University of Alabama at Birmingham, 35294, USA.

出版信息

J Clin Invest. 1995 Dec;96(6):2980-9. doi: 10.1172/JCI118370.

DOI:10.1172/JCI118370
PMID:8675670
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC186010/
Abstract

Specific killing of erbB-2-overexpressing tumor cells can be achieved using expression of an intracellular antibody directed against the erbB-2 oncoprotein. We have developed a strategy using a recombinant adenovirus encoding an anti-erbB-2 single chain antibody to achieve targeted tumor cell killing in vivo and can show significantly prolonged survival of animals carrying a human ovarian carcinoma tumor burden within their peritoneal cavities. This strategy of gene therapy for ovarian carcinoma offers the potential to achieve highly specific, targeted killing of human tumor cells and thus establishes the rationale to undertake human clinical trials on this basis.

摘要

使用针对erbB-2癌蛋白的细胞内抗体的表达，可以实现对erbB-2过表达肿瘤细胞的特异性杀伤。我们已经开发出一种策略，利用编码抗erbB-2单链抗体的重组腺病毒在体内实现靶向肿瘤细胞杀伤，并且可以显著延长腹腔内携带人卵巢癌肿瘤负荷的动物的生存期。这种卵巢癌基因治疗策略有可能实现对人类肿瘤细胞的高度特异性靶向杀伤，从而在此基础上确立进行人类临床试验的理论依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/690a8d6e11da/jcinvest00018-0450-f.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/cf07940144f4/jcinvest00018-0448-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/771fe25936cc/jcinvest00018-0448-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/26abdc9887da/jcinvest00018-0448-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/68ed42f71dad/jcinvest00018-0447-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/100280a69201/jcinvest00018-0447-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/4fab21099f73/jcinvest00018-0449-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/0833f0336580/jcinvest00018-0449-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/5abdc429f044/jcinvest00018-0449-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/bd8f7dc42699/jcinvest00018-0450-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/ad34851956c0/jcinvest00018-0450-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/585d97421050/jcinvest00018-0450-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/a0f703a9b22e/jcinvest00018-0450-d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/69e7b74144f3/jcinvest00018-0450-e.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/690a8d6e11da/jcinvest00018-0450-f.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/cf07940144f4/jcinvest00018-0448-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/771fe25936cc/jcinvest00018-0448-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/26abdc9887da/jcinvest00018-0448-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/68ed42f71dad/jcinvest00018-0447-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/100280a69201/jcinvest00018-0447-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/4fab21099f73/jcinvest00018-0449-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/0833f0336580/jcinvest00018-0449-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/5abdc429f044/jcinvest00018-0449-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/bd8f7dc42699/jcinvest00018-0450-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/ad34851956c0/jcinvest00018-0450-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/585d97421050/jcinvest00018-0450-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/a0f703a9b22e/jcinvest00018-0450-d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/69e7b74144f3/jcinvest00018-0450-e.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6163/186010/690a8d6e11da/jcinvest00018-0450-f.jpg

相似文献

1
Targeted tumor killing via an intracellular antibody against erbB-2.通过针对erbB-2的细胞内抗体进行靶向肿瘤杀伤。
J Clin Invest. 1995 Dec;96(6):2980-9. doi: 10.1172/JCI118370.
2
Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis.针对erbB-2的细胞内抗体通过凋亡介导靶向肿瘤细胞清除。
Cancer Gene Ther. 1996 Mar-Apr;3(2):89-98.
3
An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2.一种细胞内抗erbB-2单链抗体对过度表达erbB-2的人乳腺癌细胞具有特异性细胞毒性。
Gene Ther. 1997 Apr;4(4):317-22. doi: 10.1038/sj.gt.3300372.
4
Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody.通过抗erbB-2单链抗体的细胞内表达介导的卵巢癌靶向根除。
Gynecol Oncol. 1995 Oct;59(1):8-14. doi: 10.1006/gyno.1995.1260.
5
Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.使用抗HER-2受体人源化单克隆抗体和DNA反应性药物治疗后，人乳腺癌异种移植瘤的缓解情况。
Oncogene. 1998 Oct 29;17(17):2235-49. doi: 10.1038/sj.onc.1202132.
6
Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv.
Gene Ther. 2002 Feb;9(4):256-62. doi: 10.1038/sj.gt.3301639.
7
Adenovirus-mediated calponin h1 gene therapy directed against peritoneal dissemination of ovarian cancer: bifunctional therapeutic effects on peritoneal cell layer and cancer cells.腺病毒介导的钙调蛋白h1基因疗法针对卵巢癌腹膜播散：对腹膜细胞层和癌细胞的双功能治疗作用
Clin Cancer Res. 2006 Sep 1;12(17):5216-23. doi: 10.1158/1078-0432.CCR-06-0674.
8
Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy.腹腔内注射携带抗erbB-2细胞内单链抗体的腺病毒用于卵巢癌基因治疗的转导效率和安全性
Gynecol Oncol. 1997 Mar;64(3):378-85. doi: 10.1006/gyno.1996.4566.
9
A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial.一种利用编码抗erbB-2单链抗体的腺病毒（AD21）的癌症基因治疗方法：一项I期试验。
Clin Cancer Res. 2000 Aug;6(8):3081-7.
10
Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma.联合转录靶向和转导靶向可提高腺病毒基因传递至卵巢癌的特异性和有效性。
Gene Ther. 2003 Jul;10(14):1198-204. doi: 10.1038/sj.gt.3301974.

引用本文的文献

1
A Small Virus to Deliver Small Antibodies: New Targeted Therapies Based on AAV Delivery of Nanobodies.一种用于递送小型抗体的病毒：基于腺相关病毒递送纳米抗体的新型靶向疗法。
Microorganisms. 2021 Sep 15;9(9):1956. doi: 10.3390/microorganisms9091956.
2
Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions.治疗性抗体的药代动力学和药效学建模：进展、挑战与未来方向
Pharmaceutics. 2021 Mar 21;13(3):422. doi: 10.3390/pharmaceutics13030422.
3
Targeted Intracellular Delivery of Antibodies: The State of the Art.

本文引用的文献

1
High-efficiency gene transfer employing adenovirus-polylysine-DNA complexes.利用腺病毒-聚赖氨酸-DNA复合物进行高效基因转移。
Nat Immun. 1994 Mar-Jun;13(2-3):141-64.
2
Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody.一种抗p185HER2抗体对人肺癌细胞系生长的抑制作用
Am J Respir Cell Mol Biol. 1993 Oct;9(4):448-54. doi: 10.1165/ajrcmb/9.4.448.
3
Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy.
抗体的靶向细胞内递送：现状
Front Pharmacol. 2018 Oct 24;9:1208. doi: 10.3389/fphar.2018.01208. eCollection 2018.
4
Neutralizing Anti-Hemagglutinin Monoclonal Antibodies Induced by Gene-Based Transfer Have Prophylactic and Therapeutic Effects on Influenza Virus Infection.基于基因转移诱导的中和抗血凝素单克隆抗体对流感病毒感染具有预防和治疗作用。
Vaccines (Basel). 2018 Jun 26;6(3):35. doi: 10.3390/vaccines6030035.
5
HCaRG/COMMD5 inhibits ErbB receptor-driven renal cell carcinoma.HCaRG/COMMD5抑制ErbB受体驱动的肾细胞癌。
Oncotarget. 2017 May 19;8(41):69559-69576. doi: 10.18632/oncotarget.18012. eCollection 2017 Sep 19.
6
State of play and clinical prospects of antibody gene transfer.抗体基因转移的进展状况与临床前景
J Transl Med. 2017 Jun 7;15(1):131. doi: 10.1186/s12967-017-1234-4.
7
State of the art in tumor antigen and biomarker discovery.肿瘤抗原和生物标志物发现的最新技术。
Cancers (Basel). 2011 Jun 9;3(2):2554-96. doi: 10.3390/cancers3022554.
8
The use of phage display to generate conformation-sensor recombinant antibodies.噬菌体展示技术生成构象传感器重组抗体。
Nat Protoc. 2012 Dec;7(12):2127-43. doi: 10.1038/nprot.2012.132. Epub 2012 Nov 15.
9
Analysis of promoters and expression-targeted gene therapy optimization based on doubling time and transfectability.基于倍增时间和转染率的启动子分析和表达靶向基因治疗优化。
FASEB J. 2011 Sep;25(9):3219-28. doi: 10.1096/fj.11-185421. Epub 2011 May 20.
10
Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer.通过 AAVrh.10 介导的基因转移持续表达具有生物活性的抗 HER2 抗体。
Cancer Gene Ther. 2010 Aug;17(8):559-70. doi: 10.1038/cgt.2010.11. Epub 2010 May 7.
erbB-2基因在人类肿瘤中的扩增与过表达：其在肿瘤发生发展中的作用、作为预后因素的意义以及作为癌症治疗靶点的潜力。
Semin Cancer Biol. 1993 Feb;4(1):19-26.
4
Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.人卵巢癌细胞中增强的c-erbB-2/neu表达与更严重的恶性程度相关，而E1A可抑制这种恶性程度。
Cancer Res. 1993 Feb 15;53(4):891-8.
5
H-ras ribozyme-mediated alteration of the human melanoma phenotype.H-ras核酶介导的人黑色素瘤表型改变。
Ann N Y Acad Sci. 1994 May 31;716:242-53; discussion 253-6. doi: 10.1111/j.1749-6632.1994.tb21716.x.
6
Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma.在人恶性间皮瘤体内模型中成功进行腺病毒介导的基因转移。
Ann Thorac Surg. 1994 Jun;57(6):1395-401. doi: 10.1016/0003-4975(94)90090-6.
7
Oncogenes and the strategy of growth factors.癌基因与生长因子策略
Cell. 1994 Dec 16;79(6):927-30. doi: 10.1016/0092-8674(94)90023-x.
8
Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component.使用单纯疱疹病毒胸苷激酶（HSVtk）基因的组织特异性表达对小鼠黑色素瘤进行全身基因治疗涉及免疫成分。
Cancer Res. 1994 Dec 1;54(23):6228-34.
9
Intracellular expression of single chain antibodies reverts ErbB-2 transformation.
J Biol Chem. 1994 Sep 30;269(39):23931-6.
10
c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties.c-erbB-2/neu过表达通过诱导转移相关特性增强人肺癌细胞的转移潜能。
Cancer Res. 1994 Jun 15;54(12):3260-6.